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G protein-coupled receptors (GPCRs) are proteins that are
important in physiological regulatory processes within the body, and
for this reason are important drug targets
When bound to an agonist, such as neurotransmitters or hormones,
the receptor adopts an active state to allow these biochemical
pathways to occur
Mutations can arise within the receptor that affect its ability to bind
its agonist
Purpose: To test whether mutations within the sodium ion binding
pocket, an allosteric site, play a role in agonist-induced receptor
activation
Hypothesis: If mutations are made within the sodium ion binding
site, then there will be an increase in agonist-induced receptor
activation due to the loss of a negative allosteric effect

Methods

A GloSensor cAMP assay was used to measure luminescence,
which was a direct output of receptor activation
HEK293H cells were co-transfected with mutant and wildtype
receptors, as well as a GloSensor plasmid
Agonist binding encouraged the production of cAMP, which when
present with luciferin, caused luminescence to occur
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Figure 2. Spontaneous activity of wildtype receptor (A) and mutant receptor S91A
(B) in the form of a time course graph. Luminescence output over time is a direct
measurement of agonist-binding. It is calculated using the slopes of the data. Activity is
reduced in S91A.

S91A remained active, indicating that there is still agonist-induced activation
that occurs
There was reduced spontaneous activity when comparing the two time
course graphs
The dose response curve show similar responsiveness between the
wildtype and mutant receptor
In summary, mutations with the sodium ion binding site play a role in the
ability of the agonist to bind the receptor
Our findings go against those found in literature as well as our original
hypothesis, as there was a decrease in agonist-induced receptor activation,
instead of an increase
More research must be completed to fully understand this concept
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Figure 3A. The rate of cAMP production as a function of adenosine concentration,
normalized to 1.0. WT response is the blue curve while mutant response is the red curve.
There is no significant difference between the two curves.
Figure 1. GloSensor Assay. Luminescence from luciferase
activity shows GPCR activity (Wang et al.)
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